Industry: Biotech

Biotech startup funding

In biotech, each round pays for one proof point, and investors price the risk left after it. Waveup prepares the materials that make that case: deck, model, valuation and investor list.

  • Investor types and 2026 funding data for drug, platform and techbio startups
  • Decks and models built around data readouts and partner deals
  • Waveup prepares investor materials for biotech companies: $3B+ raised for 600+ startups since 2014

In short

What is biotech startup funding?

Biotech startup funding is the money drug, platform and techbio companies raise to reach their next scientific proof point. It comes from grants, angels, company builders, specialist funds, pharma venture arms and lenders. Biotech startups raised more than $9.1B of venture money in the first half of 2026. Investors favour companies with a drug already in human trials.

Who it's for
Therapeutics, platform and techbio startups, pre-seed to Series D+
What we build
Investor deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Is biotech startup funding improving in 2026?

For companies with human data, yes. New companies built on early science still struggle to close a first round.

The opportunity

Big drugmakers need new medicines, and they buy many of them from startups.

  • Most late-stage drugs at the largest drugmakers now come from outside
  • Buyers often acquire companies before they have clinical data
  • AI is drawing new investors into health and biotech, including tech companies

The problem

Biotech is getting a smaller slice of venture money. Less than 9% of US startup funding went to biotech companies in 2025.

Market size

Why do big drugmakers need biotech startups?

Large drugmakers buy many of their future medicines from young companies. Acquirers agreed to pay more than $38B for venture-backed biotechs in 2024 and 2025. Four forces keep that demand high:

  • Outside sourcing: 61% of late-stage drugs at the 20 biggest R&D spenders came from outside in 2025
  • Rising costs: one new drug cost $2.67B to develop in 2025, from discovery to launch
  • Obesity drugs: without GLP-1 and GIP drugs, big pharma's forecast R&D return was just 2.9% in 2025
  • Early buyouts: half or more of private biopharma M&A targets are preclinical or in Phase I
Average cost to develop one drug at the 20 biggest R&D spenders: $1.5B in 2015, $2.4B in 2019 and $2.7B in 2025.

Biotech in 2026, in six numbers

79

new medicines launched worldwide in 2025, by IQVIA's count

30

of those 2025 launches happened only in China

$598M

average forecast peak sales of a late-stage drug at the 20 biggest R&D spenders (2025)

38

biotech acquisitions agreed in 2026 by mid-July, the best pace in years

$925M

median upfront payment in 2025 sales of venture-backed biopharma companies

$3.05B

paid in cash by Johnson & Johnson for Halda Therapeutics, an oral cancer drug developer, in late 2025

Venture capital

Where is biotech venture money going in 2026?

Biotech venture money rose in the first half of 2026, carried by megarounds. First financings for new companies were $1.2B in Q1, tied for the lowest quarter since 2024.

Biopharma venture investment: $7.7B in Q1 2024, $7.9B in Q4 2025 and $5.2B in Q1 2026; first financings $2.8B, $1.8B and $1.2B.
$9.1B+

raised by venture-backed biotech startups in the first half of 2026, the highest first half since 2022

76%

of that money came in megarounds of $100M or more

$2.1B

raised by AI drug discovery company Isomorphic Labs in the first half of 2026

Who invests in biotech startups?

Company builders, specialist biotech funds, healthcare investors, pharma venture arms, lenders and state agencies. Each row is one example of a type; our guide to VCs investing in life sciences names many more.

Investor
Type and base
Biotech companies backed
Stage or cheque
Third Rock Ventures
Biotech company builder, Boston
Revolution Medicines, Tango Therapeutics, Candid Therapeutics
Not stated
Frazier Life Sciences
Biotech investor, venture and public strategies; Palo Alto, San Diego, Boston, Seattle
Halda Therapeutics, BridgeBio, Maze Therapeutics
Seed to public companies
Sofinnova Partners
Life sciences VC, Paris, London and Milan
Ascendis Pharma, AAVantgarde Bio, Latent Labs
Seed to later stage, including a techbio strategy
OrbiMed
Healthcare investor, about $21B managed, 12 locations
Treeline Biosciences, Mirador Therapeutics, Avenzo Therapeutics
Early-stage private companies to large multinationals
Sanofi Ventures
Corporate venture arm of Sanofi
Epicrispr Biotechnologies, Character Biosciences, i2O Therapeutics
Seed to Series B and beyond
K2 HealthVentures
Debt financing for life sciences and healthcare, Boston and New York
X4 Pharmaceuticals, Cartesian Therapeutics, Vedanta Biosciences
Customised debt; also equity and converts
CIRM
California state agency for stem cell and gene therapies
Rocket Pharmaceuticals (a gene therapy trial)
Preclinical research to clinical trials; $8.5B entrusted since 2004

Investor database

Biotech investors in our database

The funds with the most biotech investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by biotech investments

  • Investments by industry

    • Healthtech & Wellness47%
    • Biotech26%
    • Pharma20%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Chicago, United States
    Invests in
    USA

    502 investments in total, 23 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness41%
    • Biotech36%
    • Pharma18%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    Boston, United States
    Invests in
    USA

    141 investments in total, 22 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness38%
    • Biotech33%
    • Pharma17%
    Rounds
    SeedSeries ASeries C+
    Average cheque
    $0–$100K$100K–$500K$500K–$1M$1M–$3M$3M–$10M
    Based in
    San Francisco, United States
    Invests in
    USA

    196 investments in total, 20 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness44%
    • Biotech27%
    • Pharma15%
    Rounds
    Series ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Boston, United States

    439 investments in total, 18 tagged Biotech.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness46%
    • Biotech25%
    • Pharma16%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    United States
    Invests in
    Israel, Europe, USA +1

    231 investments in total, 17 tagged Biotech.Open the full fund profile

From our investor database.

What makes a biotech round hard to close?

We asked 56 VCs why they say no for our Fundraising 2025 study. Revenue growth, unit economics, burn and missed milestones topped the list. Defensibility and crowded categories came next. Before revenue, a biotech is judged on burn and milestones.

Investors want human data

Investors now favour drugs that are already being tested in people. About two in three rounds in the first half of 2026 went to companies with a drug in human testing.

What investors ask

  • When will you have human data, and what will it show?

What your deck shows

  • The first trial: design, endpoint and date
  • What a positive readout does to your value

Few first rounds

First financings fell to $1.2B in Q1 2026, tied for the lowest quarter since 2024. Some money that once backed seed-stage science now funds companies built on licensed drugs from China or elsewhere.

What investors ask

  • Why back your science instead of a licensed drug with data?

What your deck shows

  • What your science can do that a licensed molecule can't
  • A lead program with a short path to the clinic

Platforms must produce drugs

Computational biology companies took three of the ten largest biopharma rounds in Q1 2026. Most of their larger deals now include a drug in clinical testing.

What investors ask

  • Which drug has your platform made, and when will it enter trials?

What your deck shows

  • One lead program the platform produced
  • Partner deals that pay for the platform

Cash runs out between readouts

Even biotechs that raised $50M or more can stall between rounds. In late 2025, Crunchbase counted over 200 private US biotechs in that position.

What investors ask

  • Does this round reach a result that changes your value?

What your deck shows

  • Months of cash left after the readout
  • A fallback plan if the data slip

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

    From $6,000

    Mechanism, first patients and next readout, in plain words.

    From $3,000

    Trial budgets, cash runway and partnering scenarios, month by month.

    From $5,000

    Risk-adjusted value per program, checked against recent deals.

    Company builders, biotech funds, pharma venture arms and lenders for your stage.

    Patents, lab data and trial files, ordered for scientific review.

    For a sale to a drugmaker, or a buyer's diligence questions.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Health
11%
of our projects on record are in healthcare and life sciences

Biotech startup funding FAQ

How do biotech startups get funding?
Most start with grants, angels or a seed round from a company builder or specialist fund. A Series A usually follows once the science holds up in other labs. Later financing comes from crossover funds, pharma venture arms and venture lenders. Many companies also license a drug to a partner, or sell before approval. Each round should pay for one clear result.
How much venture capital goes into biotech in 2026?
What do investors look for in a biotech startup?
Can a biotech startup get grants instead of equity?
Who buys biotech startups, and for how much?
How much does help with a biotech raise cost?

Raising for a biotech company?

Tell us about your lead program and your next readout. We'll tell you how investors are likely to read your round.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?